Harvard Bioscience Schedules Fourth Quarter 2021 Earnings Conference Call for March 8, 2022 at 8:00 AM ET
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) is set to announce its fourth-quarter financial results for the period ending December 31, 2021, on March 8, 2022, prior to market opening. The company will hold a conference call at 8:00 a.m. Eastern Time to discuss these results. Investors can participate by dialing the provided numbers or via the live webcast accessible through their website. Harvard Bioscience specializes in developing technologies for fundamental research and drug development, serving various sectors from academia to pharmaceuticals.
Details
News Market Reaction – HBIO
The recorded move for HBIO in the trading session of this news was +2.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2021 before the market opens on March 8, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID #1749525.
The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, go to http://investor.harvardbioscience.com/ – Events & Presentations.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact
Michael Rossi
Chief Financial Officer
(508) 893-8999
mrossi@harvardbioscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.